Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O, Kassambara A, Moreaux J.

Theranostics. 2019 Jan 1;9(2):540-553. doi: 10.7150/thno.28374. eCollection 2019.

2.

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, Ceballos P, Cartron G, Hose D, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2019 May;96(3):209-214. doi: 10.1002/cyto.b.21730. Epub 2018 Nov 12.

PMID:
30417559
3.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.

4.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

5.

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, Boireau S, Seckinger A, Hose D, Klein B, Moreaux J.

Oncotarget. 2017 Oct 30;8(58):98931-98944. doi: 10.18632/oncotarget.22131. eCollection 2017 Nov 17.

6.

Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.

Alaterre E, Raimbault S, Garcia JM, Rème T, Requirand G, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2018 May;94(3):484-492. doi: 10.1002/cyto.b.21590. Epub 2017 Sep 19.

7.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.

8.

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, Klein B.

Oncotarget. 2012 Nov;3(11):1335-47.

9.

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.

Moreaux J, Rème T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Mol Cancer Ther. 2012 Dec;11(12):2685-92. doi: 10.1158/1535-7163.MCT-12-0721. Epub 2012 Oct 18.

10.

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Moreaux J, Hose D, Kassambara A, Reme T, Moine P, Requirand G, Goldschmidt H, Klein B.

Blood. 2011 Jan 27;117(4):1280-90. doi: 10.1182/blood-2010-04-279760. Epub 2010 Nov 19.

11.

Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection.

Caraux A, Perez-Andres M, Larroque M, Requirand G, Lu ZY, Kanouni T, Rossi JF, Orfao A, Klein B.

Immunology. 2011 Feb;132(2):266-72. doi: 10.1111/j.1365-2567.2010.03361.x. Epub 2010 Oct 13.

12.

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouillé V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A, Klein B.

Br J Cancer. 2009 Oct 6;101(7):1051-8. doi: 10.1038/sj.bjc.6605241.

13.

Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

Condomines M, Hose D, Rème T, Requirand G, Hundemer M, Schoenhals M, Goldschmidt H, Klein B.

J Immunol. 2009 Jul 15;183(2):832-40. doi: 10.4049/jimmunol.0803298. Epub 2009 Jun 19.

14.

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De Vos J, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B.

Oncogene. 2006 Nov 16;25(54):7180-91. Epub 2006 May 29.

15.

Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.

Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E, Baudard M, Requirand G, Duperray C, Schved JF, Rossi JF, Tarte K, Klein B.

J Immunol. 2006 Jun 1;176(11):6631-9. Erratum in: J Immunol. 2006 Oct 15;177(8):5748.

16.
17.

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.

De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Rème T, Jourdan M, Rossi JF, Ørntoft T, Klein B.

Oncogene. 2002 Oct 3;21(44):6848-57.

18.

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.

De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B.

Blood. 2001 Aug 1;98(3):771-80.

PMID:
11468178

Supplemental Content

Loading ...
Support Center